Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lax 510(k) Labeling Rules Alleged By Citizen Petition Citing Lumenis Device

This article was originally published in The Gray Sheet

Executive Summary

Labeling for 510(k)-cleared devices should include a notice informing consumers that FDA sign-off is based on applicant claims not verified by the agency, according to an Oct. 4 citizen petition

You may also be interested in...



ClearLight Acne Treatment DTC Advertising Will Follow More Laser Placement

Lumenis plans to launch a direct-to-consumer advertising campaign by the first quarter of 2003 in support of its ClearLight laser acne treatment system, which received FDA 510(k) clearance on Aug. 19

ESC Medical $203 Mil. Deal Ensures Coherent Ophthalmic Laser Portfolio

ESC Medical Systems' $203 mil. purchase of Coherent Medical Group gives it an entry into the high-growth ophthalmic laser market and strengthens the Israeli firm's presence in the U.S.

MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In

The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel